BUPRENEX
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Dec 1981
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 14h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BUPRENEX is a small-molecule injectable opioid agonist-antagonist analgesic approved in 1981. The specific indications and mechanism of action are not documented in available data, but buprenorphine formulations are typically used for pain management and opioid use disorder treatment. This product represents a legacy injectable formulation in a mature therapeutic category.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), suggesting a defensive commercial posture and potentially smaller, specialized teams focused on retention.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
BUPRENEX currently has zero linked job openings, reflecting its mature, LOE-approaching status. Roles supporting this product focus on market defense, compliance, and operational continuity rather than growth or innovation.
Brand ManagerField Sales Representative
Worked on BUPRENEX at Indivior? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.